About the Company
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CDTX News
Cidara Therapeutics files patent for synthesis of conjugates for treating viral infections
Discover Cidara Therapeutics' innovative patent for synthesizing viral infection treatments. Learn about conjugates with neuraminidase inhibitors and Fc domain monomers.
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and ...
Larimar: Q4 Earnings Snapshot
BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $13 million in its fourth quarter. On a per-share basis, the Bala Cynwyd, ...
Lava gets $7M from Pfizer as trial for cancer drug advances
LAVA Therapeutics (NASDAQ:LVTX) announced Tuesday that Pfizer (PFE) had reached a key milestone in its clinical program for ...
Applied Molecular Transport files patent for oral delivery of therapeutic payload using carrier-payload complex
Discover the innovative patent by Applied Molecular Transport Inc. for efficient delivery of therapeutic payloads using carrier-payload complexes derived from Cholix polypeptides. Explore the ...
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in ...
Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a price ...
Larimar Therapeutics to Present at Global Biopharma Conference in Miami
Larimar Therapeutics, Inc. (Nasdaq: LRMR), a biotechnology company specializing in the development of gene therapies, ...
Loading the latest forecasts...